Notice 27 Mar 2025 regulation, business compliance, dea, controlled substances, cannabis, drug enforcement

🍃DEA Notice on Bulk Manufacturing of Controlled Substances

The Drug Enforcement Administration (DEA) is providing notice of an application it has received from an entity applying to be registered to manufacture in bulk basic class(es) of controlled substances listed in schedule I. DEA intends to evaluate this and other pending applications according to its regulations governing the program of growing marihuana for scientific and medical research under DEA registration.

Learn More
Notice 27 Mar 2025 compliance, regulation, manufacturing, pharmaceutical, dea, controlled substances, cannabis, bulk manufacturing

🌿DEA Notice for Bulk Manufacturer of Marihuana

The Drug Enforcement Administration (DEA) is providing notice of an application it has received from an entity applying to be registered to manufacture in bulk basic class(es) of controlled substances listed in schedule I. DEA intends to evaluate this and other pending applications according to its regulations governing the program of growing marihuana for scientific and medical research under DEA registration.

Learn More
Notice 27 Mar 2025 regulation, manufacturing, pharmaceutical, dea, controlled substances, cannabis

🌿Royal Emerald Pharmaceuticals' Application for Controlled Substances Registration

Royal Emerald Pharmaceuticals has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 27 Feb 2025 manufacturing, business registration, controlled substances, cannabis, regulatory compliance, dea, drug policies

🌿Groff NA Hemplex LLC's Controlled Substances Manufacturing Application

Groff Hemplex LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

Learn More
Compliance, Consumer Trends, Regulatory Information 16 Jan 2025 fda, cannabis, regulations, cbd, veterinary medicine, animal health

🐾FDA Seeks Input on Cannabis-Derived Products in Veterinary Use

The Food and Drug Administration (FDA, the Agency, or we) is soliciting comments from the public, particularly veterinarians, related to the use of cannabis-derived products (CDPs) in animals, with an emphasis on cannabidiol (CBD) products and general trends associated with those products, including information about: usage trends (e.g., product selection, indications, etc.), quality standards, benefits of use, potential drug interactions, adverse events and safety problems, and toxicological concerns. This information will enhance the Center for Veterinary Medicine's (CVM's) knowledge of potential safety signals associated with these products, in addition to aiding our understanding of veterinarians' experiences related to the use of CDPs for their animal patients.

Learn More